Equities Analysts Issue Forecasts for PRQR Q2 Earnings

ProQR Therapeutics N.V. (NASDAQ:PRQR) – Equities researchers at HC Wainwright issued their Q2 2026 earnings estimates for ProQR Therapeutics in a research report issued on Monday, March 16th. HC Wainwright analyst A. Ghosh expects that the biopharmaceutical company will post earnings per share of ($0.13) for the quarter. The consensus estimate for ProQR Therapeutics’ current full-year earnings is ($0.31) per share. HC Wainwright also issued estimates for ProQR Therapeutics’ Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.09) EPS, FY2026 earnings at ($0.43) EPS, FY2027 earnings at ($0.42) EPS, FY2028 earnings at ($0.27) EPS and FY2029 earnings at ($0.13) EPS.

Several other equities research analysts also recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of ProQR Therapeutics in a report on Thursday, January 22nd. Wall Street Zen raised ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Saturday, March 14th. Citigroup reiterated a “market outperform” rating on shares of ProQR Therapeutics in a research note on Friday, March 13th. Finally, Oppenheimer initiated coverage on shares of ProQR Therapeutics in a research report on Thursday, March 12th. They set an “outperform” rating and a $9.00 price objective on the stock. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $6.80.

ProQR Therapeutics Stock Down 7.6%

PRQR stock opened at $1.59 on Wednesday. The business has a 50 day moving average of $1.61 and a 200 day moving average of $2.05. The firm has a market cap of $167.52 million, a PE ratio of -3.46 and a beta of 0.21. ProQR Therapeutics has a twelve month low of $1.07 and a twelve month high of $3.10.

ProQR Therapeutics (NASDAQ:PRQR) last issued its quarterly earnings results on Thursday, March 12th. The biopharmaceutical company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01). The company had revenue of $5.50 million during the quarter, compared to the consensus estimate of $6.12 million. ProQR Therapeutics had a negative return on equity of 65.89% and a negative net margin of 255.83%.

Hedge Funds Weigh In On ProQR Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PRQR. Privium Fund Management B.V. increased its holdings in shares of ProQR Therapeutics by 7.2% in the 4th quarter. Privium Fund Management B.V. now owns 5,357,762 shares of the biopharmaceutical company’s stock worth $10,823,000 after purchasing an additional 359,475 shares in the last quarter. Affinity Asset Advisors LLC raised its stake in shares of ProQR Therapeutics by 6.5% in the second quarter. Affinity Asset Advisors LLC now owns 3,499,512 shares of the biopharmaceutical company’s stock worth $7,139,000 after purchasing an additional 215,000 shares during the last quarter. Aberdeen Group plc lifted its holdings in shares of ProQR Therapeutics by 28.4% during the fourth quarter. Aberdeen Group plc now owns 2,950,676 shares of the biopharmaceutical company’s stock valued at $5,960,000 after purchasing an additional 651,853 shares in the last quarter. Sio Capital Management LLC boosted its position in shares of ProQR Therapeutics by 1.0% during the second quarter. Sio Capital Management LLC now owns 2,075,139 shares of the biopharmaceutical company’s stock valued at $4,233,000 after buying an additional 20,546 shares during the last quarter. Finally, Ikarian Capital LLC increased its holdings in ProQR Therapeutics by 67.2% in the 4th quarter. Ikarian Capital LLC now owns 1,492,229 shares of the biopharmaceutical company’s stock worth $3,014,000 after buying an additional 600,000 shares in the last quarter. 32.65% of the stock is owned by institutional investors.

More ProQR Therapeutics News

Here are the key news stories impacting ProQR Therapeutics this week:

• Neutral Sentiment: ProQR presented at The Citizens Life Sciences Conference (transcript available). The presentation provides investor visibility into management’s messaging and any program status updates but did not by itself announce new trial readouts or financing. ProQR Therapeutics N.V. (PRQR) Presents at The Citizens Life Sciences Conference 2026 Transcript
• Neutral Sentiment: Coverage note summarizing HC Wainwright’s Q1/Q4 forecasts appeared in the press; it flags analyst expectations but is a reporting item rather than a primary company release. Investors use these writeups to see analyst assumptions and compare to company guidance. What is HC Wainwright’s Forecast for PRQR Q1 Earnings?
• Negative Sentiment: HC Wainwright materially lowered its EPS forecasts across multiple years and quarters, increasing projected losses for ProQR (e.g., FY2026 now ~($0.43)/share vs prior ~($0.13); FY2027–FY2029 forecasts were also cut). Those downward revisions widen expected losses and imply a longer timeline to profitability or commercial revenue, which tends to pressure valuation for a small-cap biotech. (See coverage summaries above.) What is HC Wainwright’s Forecast for PRQR Q1 Earnings?

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.